CTSO vs. STIM, SGHT, MGRM, NYXH, INGN, CVRX, KRMD, INFU, SI, and CV
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Neuronetics (STIM), Sight Sciences (SGHT), Monogram Orthopaedics (MGRM), Nyxoah (NYXH), Inogen (INGN), CVRx (CVRX), KORU Medical Systems (KRMD), InfuSystem (INFU), Shoulder Innovations (SI), and CapsoVision (CV). These companies are all part of the "medical equipment" industry.
Cytosorbents vs. Its Competitors
Neuronetics (NASDAQ:STIM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.
Cytosorbents has a net margin of -25.58% compared to Neuronetics' net margin of -43.47%. Cytosorbents' return on equity of -111.97% beat Neuronetics' return on equity.
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by insiders. Comparatively, 7.3% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Neuronetics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
In the previous week, Cytosorbents had 1 more articles in the media than Neuronetics. MarketBeat recorded 2 mentions for Cytosorbents and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.88 beat Cytosorbents' score of 1.33 indicating that Neuronetics is being referred to more favorably in the media.
Cytosorbents has lower revenue, but higher earnings than Neuronetics. Cytosorbents is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
Neuronetics presently has a consensus target price of $7.00, indicating a potential upside of 103.49%. Cytosorbents has a consensus target price of $5.50, indicating a potential upside of 487.92%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Neuronetics.
Summary
Neuronetics beats Cytosorbents on 8 of the 15 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access